后房型有晶状体眼人工晶状体植入术矫正近视与近视性散光:10年回顾性随访研究
该回顾性观察性病例系列纳入61例患者114眼,评估植入式胶原蛋白晶状体(ICL)植入矫正近视及近视性散光的10年安全性、有效性、可预测性、稳定性及不良事件。结果显示10年时安全性指数0.88±0.15、有效性指数0.66±0.26,71.4%和87.1%的眼在目标等效球镜矫正±0.5 D和±1.0 D以内,内皮细胞丢失5.3%,10.5%眼发生前囊下白内障,无威胁视力并发症。
要点
- 10年时平均logMAR裸眼与矫正远视力分别为-0.01±0.24和-0.18±0.07。
- 10年时71.4%和87.1%的眼在目标等效球镜±0.5 D和±1.0 D以内。
- 12/114眼(10.5%)在5-10年随访期间发生前囊下白内障,其中4眼(3.5%)有症状并行ICL取出联合超声乳化手术。
核心结论
- ICL植入在10年长期随访中对近视及近视性散光的矫正于安全性、有效性、可预测性和稳定性各项指标均显示良好总体结果。
研究设计与样本
- 回顾性观察性病例系列,纳入61例患者114眼,行ICL植入矫正近视及近视性散光。
- 评估术前及术后6个月(106眼)、1年(94眼)、3年(58眼)、5年(65眼)、8年(89年)和10年(70眼)的安全性、有效性、可预测性、稳定性及不良事件,仅分析各随访时间点有临床数据的眼。
主要发现
- 术后10年平均logMAR裸眼远视力为-0.01±0.24,矫正远视力为-0.18±0.07。
- 平均安全性指数为0.88±0.15,平均有效性指数为0.66±0.26。
- 术后10年71.4%的眼在目标等效球镜矫正±0.5 D以内,87.1%的眼在±1.0 D以内。
- 平均眼压术前为13.1±2.4 mmHg,术后10年为13.1±2.9 mmHg。
- 术后10年平均内皮细胞丢失为5.3%;114眼中12眼(10.5%)在5-10年随访期间发生前囊下白内障,其中4眼(3.5%)有症状并行ICL取出联合超声乳化手术;观察期间无威胁视力的并发症发生。
局限性
- 本研究为回顾性观察性病例系列。
- 仅分析各随访时间点有临床数据的眼,各时间点样本量不同(6个月106眼、1年94眼、3年58眼、5年65眼、8年89眼、10年70眼)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the 10-year clinical outcomes of implantable collamer lens (ICL) implantation for myopia and astigmatism. DESIGN: Retrospective observational case series. METHODS: This study included 114 eyes of 61 patients who underwent ICL implantation for correction of myopia and myopic astigmatism. We assessed the safety, efficacy, predictability, stability, and adverse events preoperatively, at 6 months (106 eyes) and 1 (94 eyes), 3 (58 eyes), 5 (65 eyes), 8 (89 eyes), and 10 (70 eyes) years postoperatively. Only the eyes with clinical data available at each follow-up time were analyzed. RESULTS: The mean logMAR uncorrected and corrected distance visual acuities were -0.01 ± 0.24 and -0.18 ± 0.07 at 10 years postsurgery. The mean indices for safety and efficacy were 0.88 ± 0.15 and 0.66 ± 0.26, respectively. At 10 years postsurgery, 71.4% and 87.1% of the eyes were within 0.5 and 1.0 diopters (D), respectively, of the attempted spherical equivalent correction. The mean intraocular pressure was 13.1 ± 2.4 mmHg preoperatively and 13.1 ± 2.9 mmHg at 10 years postoperatively. The mean endothelial cell loss was 5.3% at 10 years postsurgery. Twelve of 114 eyes (10.5%) developed anterior subcapsular cataract during 5-10 years' follow-up; among these, 4 eyes (3.5%) were symptomatic and ICL explantation and phacoemulsification surgery were performed. No vision-threatening complications occurred during the observation period. CONCLUSION: ICL implantation offered good overall outcomes in all measures of safety, efficacy, predictability, and stability for the correction of myopia and myopic astigmatism throughout a long-term follow-up period of 10 years.
引用
- Nakamura T, Isogai N, Kojima T, et al. Posterior Chamber Phakic Intraocular Lens Implantation for the Correction of Myopia and Myopic Astigmatism: A Retrospective 10-Year Follow-up Study. Am J Ophthalmol. 2019. PMID: 31078536. doi:10.1016/j.ajo.2019.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。